MITO - Stealth Bio slips as blindness trial fails to meet main goal

Stealth BioTherapeutics (NASDAQ:MITO) is trading lower on Monday after the clinical-stage biotech said that its blindness therapy, elamipretide, did not meet the primary endpoint in a mid-stage trial for geographic atrophy (GA) secondary to dry age-related macular degeneration. The 176-patient ReCLAIM-2 trial was designed to evaluate elamipretide over 48 weeks in GA patients. According to its topline data, the placebo-controlled trial did not meet the primary endpoint of the mean change in low luminance visual acuity (LLVA) and GA progression, the company said. Detailing results for a key secondary endpoint, Stealth (MITO) said that the elamipretide-treated patients indicated >15% improvement in LLVA with 2+ lines of vision at Week 48. "The categorical improvement in LLVA is a potentially important finding for patients with GA….," the lead investigator of the study Jeffrey Heier, who is also a director at Ophthalmic Consultants of Boston said. In March, Stealth (MITO) shares surged in reaction

For further details see:

Stealth Bio slips as blindness trial fails to meet main goal